利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

36 条记录 (耗时 0.015 秒)

    A METHOD FOR DIAGNOSING APS USING DETERMINATION OF ANTI-PAR1 ANTIBODIES
    3.
    发明公开
    A METHOD FOR DIAGNOSING APS USING DETERMINATION OF ANTI-PAR1 ANTIBODIES 审中-公开
    使用抗PAR1抗体测定来诊断APS的方法

    公开(公告)号：EP3298408A1

    公开(公告)日：2018-03-28

    申请号：EP16724366.6

    申请日：2016-05-17

    申请人： Celltrend GmbH

    发明人： HEIDECKE, Harald ,  SCHULZE-FORSTER, Kai

    IPC分类号： G01N33/564 ,  G01N33/68

    CPC分类号： G01N33/564 ,  G01N33/6893 ,  G01N2800/226

    摘要： The application relates to a method for diagnosis of an antiphospholipid syndrome (APS) in a subject, wherein presence or absence of an anti-protease-activated receptor 1 (PAR1) antibody is detected in a sample from the subject diagnosed, and wherein the presence of an anti-PAR1 antibody is indicative of the disease. Furthermore, it relates to the use of PAR1 for the diagnosis of APS, as well as to a method of removing anti-PAR1 antibodies from isolated blood of a subject upon detection of said anti-PAR1 antibodies in a sample of said patient.

    DIAGNOSIS OF AN AUTOIMMUNE DISEASE USING DETECTION OF ANTIBODIES DIRECTED AGAINST C5A-RECEPTOR
    4.
    发明公开
    DIAGNOSIS OF AN AUTOIMMUNE DISEASE USING DETECTION OF ANTIBODIES DIRECTED AGAINST C5A-RECEPTOR 审中-公开
    使用检测抗C5a受体的抗体诊断自身免疫性疾病

    公开(公告)号：EP3213075A1

    公开(公告)日：2017-09-06

    申请号：EP15787610.3

    申请日：2015-10-30

    申请人： CellTrend GmbH

    发明人： HEIDECKE, Harald ,  SCHULZE-FORSTER, Kai

    IPC分类号： G01N33/564

    CPC分类号： G01N33/564 ,  G01N2333/70596 ,  G01N2333/726 ,  G01N2800/101 ,  G01N2800/104 ,  G01N2800/347

    摘要： The application relates to a method for diagnosis of an autoimmune disease, comprising the step of determining the presence or absence of antibodies directed against CSa-receptor in a sample of the subject to be diagnosed, wherein the presence of antibodies directed against CSa-receptor is indicative of an autoimmune disease in said subject. Furthermore, the application relates to kits comprising C5a-receptor or an immunogenic fragment thereof and the use of CSa-receptor.

    摘要翻译： 本申请涉及诊断自身免疫性疾病的方法，包括确定待诊断受试者的样品中针对C5a-受体的抗体的存在或不存在的步骤，其中针对C5a-受体的抗体的存在是 指示所述受试者中的自身免疫性疾病。 此外，本申请涉及包含C5a受体或其免疫原性片段的试剂盒以及C5a受体或其免疫原性片段用于诊断自身免疫性疾病的用途。

    VERFAHREN ZUR VORHERSAGE EINES TRANSPLANTATABSTOSSUNGSRISIKOS UND IMMUNOLOGISCHER TESTKIT
    6.
    发明授权
    VERFAHREN ZUR VORHERSAGE EINES TRANSPLANTATABSTOSSUNGSRISIKOS UND IMMUNOLOGISCHER TESTKIT 有权
    方法用于预测TRANSPLANTATABSTOSSUNGSRISIKOS及免疫检测试剂盒

    公开(公告)号：EP1393076B1

    公开(公告)日：2005-06-15

    申请号：EP02738068.2

    申请日：2002-05-13

    申请人： Celltrend GmbH

    发明人： SCHULZE-FORSTER, Kai ,  HEIDECKE, Harald

    IPC分类号： G01N33/564 ,  G01N33/566 ,  G01N33/68

    CPC分类号： G01N33/564 ,  G01N2800/245 ,  Y10S435/975

    摘要： The invention relates to a method and an immunological test kit for predicting the risk of transplant rejection by detecting anti-AT1 receptor auto-antibodies in biological materials of a patient to be examined, e.g. by an immune reaction with the AT1 receptor or functionally analogous peptides or proteins thereof. The invention also relates to the use of the AT1 receptor or functionally analogous peptides or proteins therof in order to predict (diagnose) the risk of transplant rejection. Said risk exists if anti-AT1 receptor auto-antibodies can be detected in biological materials e.g. in body fluids or tissues.

    PROGNOSIS OF ADVERSE OUTCOMES BY DETERMINATION OF MIDKINE LEVELS AFTER CARDIOVASCULAR STRESS
    9.
    发明公开
    PROGNOSIS OF ADVERSE OUTCOMES BY DETERMINATION OF MIDKINE LEVELS AFTER CARDIOVASCULAR STRESS 审中-公开

    公开(公告)号：EP3373799A1

    公开(公告)日：2018-09-19

    申请号：EP16797821.2

    申请日：2016-11-11

    申请人： Celltrend GmbH

    发明人： HEIDECKE, Harald ,  MERTENS, Peter

    IPC分类号： A61B5/00 ,  G01N33/68

    CPC分类号： A61B5/4884 ,  A61B5/4836 ,  A61B5/4848 ,  A61B5/7275 ,  G01N33/74 ,  G01N2333/475 ,  G01N2800/32 ,  G01N2800/56 ,  G06F19/00

    摘要： The present application relates to a method for the prognosis of adverse outcomes in a subject comprising the following steps: (i) determining the midkine level in a sample of said subject; and (ii) comparing the determined midkine level to a control midkine level; wherein said sample is taken after the subject has been subjected to cardiovascular stress; wherein said control midkine level is derived from control sample(s) from one or more subjects not showing adverse outcomes, wherein the control sample(s) have been taken after said one or more subjects not showing adverse outcomes have been subjected to cardiovascular stress; and wherein a decreased determine midkine level as compared to the control midkine level is indicative of an adverse outcome. Further it relates to a method for the prognosis of adverse outcomes in a subject comprising the following steps: (i) determining in samples of said subject the increase in midkine levels (Δmidkine value) during cardiovascular stress; and (ii) comparing the determined Δmidkine value to a control Δmidkine value; wherein said control Δmidkine value is derived from one or more subjects not showing adverse outcomes; wherein a decreased determined Δmidkine value as compared to the control Δmidkine value is indicative of an adverse outcome. It also relates to the use of a midkine antibody or an antigen binding fragment thereof for the prognosis of adverse outcomes in a subject undergoing dialysis therapy. Also encompassed is midkine for use in the treatment or the prevention of an adverse outcome, wherein midkine is administered to the subject.